Diagnostic applications of nuclear medicine: Vulvar cancer
Nuclear Oncology: From Pathophysiology to Clinical Applications, Page: 1115-1138
2022
- 1Citations
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Vulvar cancer is an uncommon malignancy in women and is less frequently seen as compared to cervical or endometrial cancer. Human papillomavirus (HPV) infection, chronic lichen simplex infection, and genital warts are considered some of the predisposing factors. While metastases occur in late-stage disease (usually via lymphatic spread), most lesions are detected in the early stages. Anatomic imaging is the mainstay for evaluation of local extent. [F]FDG PET/CT imaging has incremental value for evaluation of equivocal lesions, assessing nodal status, and detecting distant metastasis. Lymphoscintigraphy for sentinel node mapping is useful for surgical planning and limiting postoperative morbidity from extensive nodal dissection. This chapter summarizes the current status and emerging trends in imaging vulvar cancer using radiopharmaceuticals.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85153817717&origin=inward; http://dx.doi.org/10.1007/978-3-031-05494-5_22; https://link.springer.com/10.1007/978-3-031-05494-5_22; https://dx.doi.org/10.1007/978-3-031-05494-5_22; https://link.springer.com/referenceworkentry/10.1007/978-3-031-05494-5_22
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know